Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
NASDAQ Jumps 4%+ This Week, While S&P, Dow Rise Over 3%
12:00am, Saturday, 10'th Oct 2020
Stocks Analysis by Zacks Investment Research covering: Citigroup Inc, Bank of America Corp, Goldman Sachs Group Inc, JPMorgan Chase & Co. Read Zacks Investment Research's latest article on Investing.c
Charles Schwab Investment Management Inc. Raises Position in Intellia Therapeutics Inc (NASDAQ:NTLA)
06:36am, Thursday, 08'th Oct 2020
Charles Schwab Investment Management Inc. grew its holdings in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 21.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The
Nobel Prize in Chemistry Is Awarded for Crispr Gene-Editing Technology
07:42pm, Wednesday, 07'th Oct 2020
Two scientists won the Nobel Prize in Chemistry for discovering a powerful tool for genome editing that has enabled relatively quick and easy modification of the building blocks of life and promises n
Thalassemia Treatment Market Size, 2020 Growth, Types, Trends, Size, Share and Top Key Players by Forecast Research 2025
10:52am, Tuesday, 06'th Oct 2020
Oct 06, 2020 (Heraldkeepers) --
Global Thalassemia Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025. Rise in...
PNC Financial Services Group Inc. Lowers Stock Position in Intellia Therapeutics Inc (NASDAQ:NTLA)
10:18am, Saturday, 03'rd Oct 2020
PNC Financial Services Group Inc. reduced its stake in Intellia Therapeutics Inc (NASDAQ:NTLA) by 44.1% during the second quarter, HoldingsChannel reports. The firm owned 12,700 shares of the company�
CAMBRIDGE, Mass., Sep 29, 2020 (GLOBE NEWSWIRE via COMTEX) --
In Vivo gene knockout and insertion data to be presented at OTS Annual Meeting...
Neuberger Berman Group LLC Sells 4,777 Shares of Intellia Therapeutics Inc (NASDAQ:NTLA)
07:54am, Monday, 28'th Sep 2020
Neuberger Berman Group LLC decreased its holdings in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 7.9% in the second quarter, according to its most recent Form 13F filing with the SEC. The ins
$14.36 Million in Sales Expected for Intellia Therapeutics Inc (NASDAQ:NTLA) This Quarter
04:52am, Thursday, 24'th Sep 2020
Equities research analysts expect Intellia Therapeutics Inc (NASDAQ:NTLA) to announce $14.36 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have issued estim
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Sep 22, 2020 (GLOBE NEWSWIRE via COMTEX) --
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Sept. 22,...
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Sep 22, 2020 (GLOBE NEWSWIRE via COMTEX) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals...
Jacobs Levy Equity Management Inc. Decreases Stock Holdings in Intellia Therapeutics Inc (NASDAQ:NTLA)
06:50am, Tuesday, 22'nd Sep 2020
Jacobs Levy Equity Management Inc. cut its holdings in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 78.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The
Intellia Therapeutics: First-Time Clinical Stage Biotech With 3 Realistic Candidates, 30% Upside (NASDAQ:NTLA)
03:13pm, Monday, 21'st Sep 2020
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a preclinical-stage genome editing company focusing on developing novel therapeutics using the genome-editing process known as CRISPR/Cas9.
Crispr: The Frontier Of Gene Editing (NASDAQ:CRSP)
04:45pm, Friday, 18'th Sep 2020
As a premier gene-editing company, CRISPR delivered stellar animal data for the blood disorder franchises (i.e., beta-thalassemia and sickle cell disease).
Fmr LLC Acquires 776,887 Shares of Intellia Therapeutics Inc (NASDAQ:NTLA)
06:22am, Thursday, 17'th Sep 2020
Fmr LLC increased its holdings in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 93.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fi
Graphite Bio Launches with $45 Million Series A Financing
12:00am, Wednesday, 16'th Sep 2020
Graphite Bio today announced a $45 million Series A financing led by founding investor Versant Ventures, together with Samsara BioCapital. Graphite Bi
